BioCryst Pharmaceuticals BCRX ORLADEYO — Total trade receivables
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNet.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's orladeyo — total trade receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's ORLADEYO — total trade receivables?
- BioCryst Pharmaceuticals (BCRX) reported ORLADEYO — total trade receivables of $102.29M in Q1 2026.
- How has BioCryst Pharmaceuticals's ORLADEYO — total trade receivables changed year-over-year?
- BioCryst Pharmaceuticals's ORLADEYO — total trade receivables increased by 13.0% year-over-year, from $90.49M to $102.29M.
- What is the long-term trend for BioCryst Pharmaceuticals's ORLADEYO — total trade receivables?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's ORLADEYO — total trade receivables has grown at a 45.0% compound annual growth rate (CAGR), from $81.08M to $358.45M.
- What does ORLADEYO — total trade receivables mean?
- This metric represents the outstanding balance of payments owed by customers for products delivered within this specific segment. Monitoring this helps assess the credit quality of the customer base and the efficiency of the company's cash collection cycle.